Company Profile
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:
- pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases);
- human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas;
- consumer health products (12%).
At the end of 2023, the group had 54 production sites throughout the world.
Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
- pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases);
- human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas;
- consumer health products (12%).
At the end of 2023, the group had 54 production sites throughout the world.
Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Source: Cofisem - Last Update: 2024-10-21
Key Executives
| Chief Executive Officer | |
| Chief Financial Officer | |
| Director Research & Development | |
| Chief Human Resources Officer | |
| Head of Investor Relations | |
| General Counsel |
Source: Cofisem - Last Update: 2024-10-21
Key Figures
| Millenium | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Net sales | 43,070 | 42,997 | 37,761 | 36,041 | 36,126 |
| Income from ordinary activities | 46,444 | 45,389 | 39,175 | 37,369 | 37,631 |
| Operating income | 7,875 | 10,656 | 8,126 | 14,141 | 3,125 |
| Cost of financial indebtedness net | 22 | 124 | 259 | 225 | 172 |
| Equity-accounted companies contribution to income | -115 | 68 | 39 | 359 | 255 |
| Net profit from discontinued activities | 0 | -101 | |||
| Net income | 5,436 | 8,484 | 6,279 | 12,350 | 2,837 |
| Net income (Group share) | 5,400 | 8,371 | 6,223 | 12,314 | 2,806 |
| Fiscal year end | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - millions | EUR - millions | EUR - millions | EUR - millions | EUR - millions |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
Source: Cofisem - Last Update: 2024-10-21
Shareholder information
| Treasury stock | |
| BlackRock, Inc. | |
| Free float | |
| L'Oréal | |
| Employees |
Source: Cofisem - Last Update: 2024-10-21
Address
Sanofi
46 Avenue de la Grande Armée
FR-75017 Paris
France
Phone number: +33 (0)1 53 77 40 00
Fax: +33 (0)1 53 77 44 63
https://www.sanofi.com
Source: Cofisem - Last Update: 2024-10-21
Contact
Please contact MyQuestion.Italy@euronext.com for Company Profile support.